CSIMarket
 

Meiragtx Holdings Plc  (MGTX)
Other Ticker:  
 

Meiragtx Holdings Plc's Working Capital Per Sales

MGTX's Working Capital and Revenue growth



MGTX Working Capital Per Revenue (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Working Capital Change 28.06 % -51.6 % 93.3 % -47.85 % -37.22 %
Y / Y Revenue Change - 5.96 % -67.1 % -40.81 % -
Working Capital Per Revenue 4.36 8.37 10.41 4.26 4.23
Total Ranking # 1831 # 2438 # 3133 # 2878 # 2999
Seq. Working Capital Change 131.26 % -43.91 % 76.69 % -44.13 % -12.59 %
Seq. Revenue Change -60.02 % 44.15 % 6.18 % - -





Comment on MGTX's Working Capital Per Revenue in the fourth quarter 2023
Meiragtx Holdings Plc's Working Capital Per Revenue in the Q4 2023 sequentially fell to 4.36 below the company average. Due to decrease of revenue year on year in the fourth quarter 2023 by -138.58%.

Within Healthcare sector 29 other companies have achieved lower Working Capital Per Revenue during the Q4 2023. While Meiragtx Holdings Plc Working Capital Per Revenue overall ranking has impoved so far in the Q4 2023 to 1831, from total ranking in the third quarter 2023 at 2438.
Working Capital Per Revenue Ranking
Within: No.
Industry # 3
Sector # 30
S&P 500 # 1831


Working Capital Per Revenue Statistics
High Average Low
15.45
8.02
1.77
(Dec 31 2019)   (Sep 30 2022)



Financial Statements
Meiragtx Holdings Plc's Working Capital $ 93 Millions Visit MGTX's Balance sheet
Meiragtx Holdings Plc's Revenues $ 2 Millions Visit MGTX's Income Statement
Where are MGTX's Sales coming from? Visit MGTX's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Dec 31 2023, within Healthcare Sector Working Capital Per Revenue
C4 Therapeutics Inc   10.68 
Co diagnostics Inc   10.46 
Dbv Technologies S a   9.52 
Delcath Systems Inc   9.30 
Caribou Biosciences Inc   7.85 
Recursion Pharmaceuticals Inc   7.73 
Ac Immune Sa  7.54 
Prothena Corporation Public Limited Company  6.78 
Lipella Pharmaceuticals Inc   6.67 
Vaxart Inc   6.61 
Foghorn Therapeutics Inc   6.54 
Werewolf Therapeutics Inc   6.41 
Arcus Biosciences Inc   6.35 
Inspiremd Inc   5.95 
Curis Inc   5.87 
Innovative Eyewear Inc   5.32 
Hookipa Pharma inc   5.24 
Mersana Therapeutics Inc   5.11 
Aadi Bioscience Inc   5.03 
Maxcyte inc   4.98 
Profound Medical Corp   4.94 
Soligenix inc   4.73 
Arcutis Biotherapeutics Inc   4.72 
Cara Therapeutics inc   4.69 
Biontech Se  4.57 
Zymeworks Inc   4.42 
Liquidia Corporation  4.41 
Meiragtx Holdings Plc  4.36 
Legend Biotech Corporation  4.24 
Marker Therapeutics inc   4.19 
Date modified: 2024-03-15T15:49:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com